What Has Been the Progress and Growth of the Liraglutide And Semaglutide Market in Recent Years?
The liraglutide and semaglutide market has seen considerable growth due to a variety of factors.
• The liraglutide and semaglutide market has seen rapid growth. It will rise from $15.19 billion in 2024 to $16.98 billion in 2025, with a CAGR of 11.8%.
This growth is attributed to the rising prevalence of diabetes, a surge in obesity-related diseases, an increase in clinical trials, greater investment in diabetes research, and rising demand for convenient treatment options.
How Does the Forecast Look for the Liraglutide And Semaglutide Market?
The liraglutide and semaglutide market is expected to maintain its strong growth trajectory in upcoming years.
• The liraglutide and semaglutide market is expected to grow rapidly, reaching $26.24 billion by 2029, at a CAGR of 11.5%.
The growth will be supported by the increasing adoption of GLP-1 receptor agonists, rising healthcare expenditure, expanding pharmaceutical product portfolios, higher disposable incomes, and a growing geriatric population susceptible to diabetes. Key trends include the integration of digital health platforms, personalized dosing strategies, advancements in drug delivery technologies, development of biosimilar versions, and AI integration in treatment decisions.
What Are The Leading Drivers Of Growth In The Liraglutide And Semaglutide Market?
The growing number of diabetic patients is expected to fuel the growth of both the liraglutide and semaglutide markets. With the rise in diabetes due to lifestyle changes, these treatments help manage blood glucose and reduce complications. The NHS in the UK identified over half a million additional individuals at risk of developing type 2 diabetes in 2023, contributing to the growth of both markets.
How Are The Segments Defined Within The Global Liraglutide And Semaglutide Market?
The liraglutide and semaglutide market covered in this report is segmented –
1) By Type: Pills, Liquid
2) By Administration: Parenteral, Oral
3) By Application: Type 2 Diabetes Mellitus, Obesity, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Pills: Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations
2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection
Pre-Book The Liraglutide And Semaglutide Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Liraglutide And Semaglutide Market?
Leading firms in the liraglutide and semaglutide markets are innovating anti-diabetic biosimilar medications to improve glucose management and mitigate heart-related issues in diabetic individuals. These anti-diabetic biosimilars, designed to provide similar health outcomes as established diabetes biologics, offer a cost-effective alternative. For example, in January 2024, Glenmark Pharmaceuticals Ltd., an Indian pharmaceutical firm, introduced a biosimilar of the widely used anti-diabetic medication, Liraglutide, marking its debut in India. This Liraglutide biosimilar aims to enhance glucose regulation in adult individuals suffering from type 2 diabetes mellitus. Its introduction implies a reduction in daily treatment expenses, making it accessible to a wider patient segment across the country. With a price point around INR 100 for a standard daily dose of 1.2 mg, it could lower treatment costs by nearly 70%, and buying it would necessitate a prescription.
Who Are the Key Players In The Liraglutide And Semaglutide Market?
Major companies operating in the liraglutide and semaglutide market are:
• Pfizer Inc.
• Merck & Co. Inc.
• Bristol-Myers Squibb
• AstraZeneca
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Otsuka Holdings Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Sumitomo Pharma Co. Ltd.
• Shionogi & Co. Ltd.
• Cadila Pharmaceuticals
• Kyowa Kirin Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Biocon
• Glenmark Pharmaceuticals Ltd.
• Bachem
• Zealand Pharma
• Shenzhen JYMed Technology Co. Ltd.Incepta Pharmaceuticals Ltd.
What Is The Most Dominant Region In The Liraglutide And Semaglutide Market?
North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
